Emergent Biosolutions (Gaithersburg, US) has purchased US and Canadian rights to Kloxxado, adding to its opioid overdose ...
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) ...
January 2025 – LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading Pharmaceutical technology company, is proud to announces ...
ANDERNACH, GERMANY - Newsaktuell - 14 January 2025 - LTS LOHMANN Therapie-Systeme AG (LTS), a leading <a target=_blank href= ...
The $50 million Patch Forward Prize, part of BARDA's Project NextGen initiative ... the platform can rapidly pivot to address pandemic or regional outbreaks of other strains.
GlobalData on MSN3d
$590m to Moderna from HHS for mRNA ‘flu vax developmentModerna is set to receive $590m in funding from the HHS to expedite the development of mRNA-based pandemic influenza vaccines ...
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Emergent Biosolutions (EBS – Research Report), with a ...
The $50 million Patch Forward Prize, part of BARDA's Project NextGen initiative ... Initially targeting drifted seasonal influenza strains, the platform can rapidly pivot to address pandemic or ...
PopVax awarded $2M for its patch-delivered mRNA influenza vaccine in collaboration with LTS Lohmann as part of BARDA’s Patch Forward Prize.
Shionogi & Co. has been awarded a $375 million project agreement by the Biomedical Advanced Research and Development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback